iBio initiated with an Outperform at LifeSci Capital

LifeSci Capital initiated coverage of iBio (IBIO) with an Outperform rating and $5 price target. iBio is advancing multiple antibody-based candidates from its AI discovery platform, with lead asset IBIO-610 targeting activin E for obesity and cardiometabolic diseases, the analyst tells investors in a research note. Early human and preclinical data from competitors like Wave (WVE) and Arrowhead (ARWR) validate the target, while IBIO-610 offers differentiation through antibody format, co-formulation potential with GLP-1s, and scalable manufacturing, the firm says. The company plans an IND-equivalent submission in 4Q26 and a Phase 1 study in 1H27.